Why Amgen Stock Was Crushing It on Wednesday

Amgen (AMGN) reported strong third-quarter results, with revenue increasing 12% year-over-year to $9.6 billion and non-GAAP net income reaching $5.64 per share, both significantly exceeding analyst expectations and driving an over 8% stock surge. The biotech firm attributed its performance to volume growth and key drug sales, prompting it to raise its full-year 2025 revenue guidance to $35.8-$36.6 billion and adjusted EPS guidance to $20.60-$21.40, signaling a positive outlook for future performance.

Analysis

Amgen (AMGN) delivered robust third-quarter results, leading to an 8.86% surge in its stock price during Wednesday's mid-session trading. The company reported a 12% year-over-year increase in total revenue, reaching $9.6 billion, which significantly exceeded the consensus analyst estimate of $8.98 billion. Non-GAAP net income also saw a 1% rise to $3.06 billion, or $5.64 per share, comfortably surpassing the $5.04 per share forecast.

This strong financial performance was primarily driven by volume growth and double-digit sales increases across Amgen's key drug portfolio. The substantial beat on both top and bottom lines indicates effective operational execution and robust market demand for its pharmaceutical products, suggesting a healthier underlying business trajectory than previously anticipated by the market.

In response to this momentum, Amgen raised its full-year 2025 guidance for both revenue and adjusted profitability. The company now projects revenue between $35.8 billion and $36.6 billion, an increase from its prior range of $35 billion to $36 billion. Similarly, the adjusted net income per share forecast was lifted to $20.60-$21.40, up from $20.20-$21.30, signaling management's confidence in sustained future growth and pipeline strength.

Key Decisions for Investors

• Investors should assess Amgen's updated 2025 guidance and strong Q3 performance as indicators of positive fundamental momentum and potential for continued earnings growth.
• Consider the implications of sustained volume growth and the strength of Amgen's drug pipeline on its long-term competitive positioning within the healthcare sector.
• Monitor future reports for continued execution against the raised guidance and any further developments in key drug sales or pipeline advancements to validate the optimistic outlook.